149 related articles for article (PubMed ID: 11069364)
1. Placebo-associated remissions in a multicentre, randomized, double-blind trial of interferon gamma-1b for the treatment of metastatic renal cell carcinoma. The Canadian Urologic Oncology Group.
Elhilali MM; Gleave M; Fradet Y; Davis I; Venner P; Saad F; Klotz L; Moore R; Ernst S; Paton V
BJU Int; 2000 Oct; 86(6):613-8. PubMed ID: 11069364
[TBL] [Abstract][Full Text] [Related]
2. Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group.
Gleave ME; Elhilali M; Fradet Y; Davis I; Venner P; Saad F; Klotz LH; Moore MJ; Paton V; Bajamonde A
N Engl J Med; 1998 Apr; 338(18):1265-71. PubMed ID: 9562580
[TBL] [Abstract][Full Text] [Related]
3. A randomized phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon gamma and human recombinant interferon alpha2B therapy in patients with metastatic renal cell carcinoma: clinical outcome and analysis of immunological parameters.
Schwaab T; Heaney JA; Schned AR; Harris RD; Cole BF; Noelle RJ; Phillips DM; Stempkowski L; Ernstoff MS
J Urol; 2000 Apr; 163(4):1322-7. PubMed ID: 10737537
[TBL] [Abstract][Full Text] [Related]
4. Single institution experience with recombinant gamma-interferon in the treatment of patients with metastatic renal cell carcinoma.
Mani S; Poo WJ
Am J Clin Oncol; 1996 Apr; 19(2):149-53. PubMed ID: 8610639
[TBL] [Abstract][Full Text] [Related]
5. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.
Bergmann L; Fenchel K; Weidmann E; Enzinger HM; Jahn B; Jonas D; Mitrou PS
Cancer; 1993 Sep; 72(5):1733-42. PubMed ID: 8348502
[TBL] [Abstract][Full Text] [Related]
6. A phase IA trial of sequential administration recombinant DNA-produced interferons: combination recombinant interferon gamma and recombinant interferon alfa in patients with metastatic renal cell carcinoma.
Ernstoff MS; Nair S; Bahnson RR; Miketic LM; Banner B; Gooding W; Day R; Whiteside T; Hakala T; Kirkwood JM
J Clin Oncol; 1990 Oct; 8(10):1637-49. PubMed ID: 2120392
[TBL] [Abstract][Full Text] [Related]
7. Preliminary results of the alternating administration of natural interferon-alpha and recombinant interferon-gamma for metastatic renal cell carcinoma.
Fujii A; Yui-En K; Ono Y; Yamamoto H; Gohji K; Takenaka A
BJU Int; 1999 Sep; 84(4):399-404. PubMed ID: 10468752
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of interferon-beta-serine in metastatic renal cell carcinoma.
Kinney P; Triozzi P; Young D; Drago J; Behrens B; Wise H; Rinehart JJ
J Clin Oncol; 1990 May; 8(5):881-5. PubMed ID: 2332772
[TBL] [Abstract][Full Text] [Related]
9. Cytoreductive radiofrequency ablation in patients with metastatic renal cell carcinoma (RCC) with small primary tumours treated with sunitinib or interferon-α.
Tsimafeyeu I; Zart JS; Chung B
BJU Int; 2013 Jul; 112(1):32-8. PubMed ID: 23746142
[TBL] [Abstract][Full Text] [Related]
10. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial.
Mickisch GH; Garin A; van Poppel H; de Prijck L; Sylvester R;
Lancet; 2001 Sep; 358(9286):966-70. PubMed ID: 11583750
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of low dose gamma-interferon in metastatic renal cell carcinoma.
Ellerhorst JA; Kilbourn RG; Amato RJ; Zukiwski AA; Jones E; Logothetis CJ
J Urol; 1994 Sep; 152(3):841-5. PubMed ID: 8051732
[TBL] [Abstract][Full Text] [Related]
12. EORTC (30885) randomised phase III study with recombinant interferon alpha and recombinant interferon alpha and gamma in patients with advanced renal cell carcinoma. The EORTC Genitourinary Group.
De Mulder PH; Oosterhof G; Bouffioux C; van Oosterom AT; Vermeylen K; Sylvester R
Br J Cancer; 1995 Feb; 71(2):371-5. PubMed ID: 7841054
[TBL] [Abstract][Full Text] [Related]
13. Does radical nephrectomy with immunochemotherapy have any superiority over embolization alone in metastatic renal cell carcinoma? A preliminary report.
Demirci D; Tatlişen A; Ekmekçioğlu O; Ozcan N; Kaya R
Urol Int; 2004; 73(1):54-8. PubMed ID: 15263794
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.
Escudier B; Pluzanska A; Koralewski P; Ravaud A; Bracarda S; Szczylik C; Chevreau C; Filipek M; Melichar B; Bajetta E; Gorbunova V; Bay JO; Bodrogi I; Jagiello-Gruszfeld A; Moore N;
Lancet; 2007 Dec; 370(9605):2103-11. PubMed ID: 18156031
[TBL] [Abstract][Full Text] [Related]
15. Feasibility of prolonged use of interferon-alpha in metastatic kidney carcinoma: a phase II study.
Kankuri M; Pelliniemi TT; Pyrhönen S; Nikkanen V; Helenius H; Salminen E
Cancer; 2001 Aug; 92(4):761-7. PubMed ID: 11550145
[TBL] [Abstract][Full Text] [Related]
16. Granulocyte-macrophage-colony stimulating factor in combination immunotherapy for patients with metastatic renal cell carcinoma: results of two phase II clinical trials.
Ryan CW; Vogelzang NJ; Dumas MC; Kuzel T; Stadler WM
Cancer; 2000 Mar; 88(6):1317-24. PubMed ID: 10717612
[TBL] [Abstract][Full Text] [Related]
17. Successful treatment of metastatic renal cell carcinoma with a biologically active dose of recombinant interferon-gamma.
Aulitzky W; Gastl G; Aulitzky WE; Herold M; Kemmler J; Mull B; Frick J; Huber C
J Clin Oncol; 1989 Dec; 7(12):1875-84. PubMed ID: 2511277
[TBL] [Abstract][Full Text] [Related]
18. Interferon therapy for metastatic renal cell carcinoma.
Swanson DA; Quesada JR
Semin Surg Oncol; 1988; 4(3):174-7. PubMed ID: 3142007
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
[TBL] [Abstract][Full Text] [Related]
20. EORTC-GU group expert opinion on metastatic renal cell cancer.
de Reijke TM; Bellmunt J; van Poppel H; Marreaud S; Aapro M
Eur J Cancer; 2009 Mar; 45(5):765-73. PubMed ID: 19157861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
